Audit: QRS - CDP-Choline for Health & Longevity

Audit conducted on 18/09/2026 08:39 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every cell traced to ER: protocol cells to ER Therapeutic Protocol (lines 325, 327, 335), time cells to ER lines 382, 197, benefits/risks to ER section headings, gates to ER lines 279-303, markers to the ER biomarker table (lines 414-420), qualitative items verbatim from ER lines 424-429.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	time_2_sub carries the ER’s “the attention signal is unreplicated in adults” (ER line 171); marker_7_target carries “No established target; track change from the individual’s own baseline” verbatim.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	“Pregnancy and breastfeeding” stays in the Contraindications gate, not the Key Interactions gate; no hedge is added to or removed from a gate item.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from ER “Populations who should avoid CDP-Choline” (lines 297-303); Key Interactions only from the ER interaction bullets (lines 279-293). No Benefit- or Risk-Modifying Factor is surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Only brand names carried are “Sinemet, Madopar”, taken from the same ER interaction bullet (ER line 279). No PMIDs, NCT IDs or author names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present; ER attributions such as “the European prescribing information” and “Ferrer” are stripped, none added.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s guarded, evidence-weighted register, including the sponsorship caveat carried into the lede.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Concrete doses, windows and biomarker targets are given without hype or alarm.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Cells state what trials used, not what should be done.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a reader; monitoring rows state what a marker detects, not what to do.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “should”, or “advised” in the QRS’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	ER glosses are applied: “parenteral” is rendered “injected”, “phosphocreatine and adenosine triphosphate” as “energy stores”.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items are noun phrases; benefit and risk tiers are single semicolon-separated lines.
2.9	It DOES NOT address the reader directly	🟢	Confirmed; the only near-address, “track change from the individual’s own baseline”, is third-person and verbatim from the ER.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Monitoring panel, titration context and sponsorship caveat all address a proactive, risk-aware reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Retains send-out tests (plasma free choline, TMAO) and a 12-week computerised cognitive battery without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No consumer-grade simplification; full biomarker panel and functional ranges are retained.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede foregrounds the healthy-ageing memory signal and its poor study quality, which is the axis that matters for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; “age-related decline” and “healthy-ageing” are used.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	“prescription medicine”, “supplement”, “gastrointestinal intolerance”, “injected” are all formal register; no “pill”, “shot”, or “taken by mouth”.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings verified byte-identical to [qrs_template] (QRS lines 445, 489, 540, 564, 578, 600, 623, 627-629, 739).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variable names present; marker_#_* expanded to marker_1..7_* and qualitative_item_# to qualitative_item_1..6, as the template intends.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against [qrs_template] shows the head, full stylesheet, all <span website="..."> hooks and the footer disclaimer are untouched; only checklist-governed variable regions differ.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section is empty and the ER uses no empty-state phrasing; the ER’s High-risk tier carries a written rationale (line 221), which item 13.5 governs instead.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1/2/3_label reproduce ER bold labels “Standard supplement regimen”, “Clinical European regimen”, “Best time of day” (ER lines 325, 327, 335); all seven marker names match the ER biomarker table verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect cells have no ER bold label to copy; their labels are lifted from ER wording (“Memory”, “attention and reaction-time” at ER line 382, “Brain Energy Reserves” heading at ER line 195).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the file; the ER’s ⭕️ and ⚠️ markers were correctly dropped. Tiers are conveyed by bold labels and the card palette.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Single .sheet with the template’s A4 print rules intact; every section is condensed to noun phrases or single lines, and no section exceeds the template’s per-section budget.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The comment opens at line 2, immediately after <!doctype html> on line 1, and closes at line 14 before any other content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble “QRS — Metadata (invisible, parsed by audit tooling)” sits before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values is echoed by any rendered element.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, correctly so because the value contains a colon; all other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: cdp_choline_2026-0918-0522_Opus_ER.md, matching the source ER’s own filename field.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the version badge of [qrs_prompt].
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0918-0826, conforming to the required format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: cdp_choline_2026-0918-0522_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all ten keys; no stray whitespace and no unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “CDP-Choline for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “CDP-Choline for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/18/2026”, the correct MM/DD/YYYY rendering of qrs_creation_date: 2026-0918-0826.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” list was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three ER Conclusion paragraphs (lines 453-457) into the four decision-relevant points: what it is, where the signal is, safety, and sponsorship bias.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“molecule the body already makes” / “prescription medicine … supplement elsewhere” → ER line 453; “strongest human signal is memory … small, short and often of poor quality” → line 453; “mild and uncommon” → line 455; “companies that sell it” → line 457.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; the strongest terms, “prescription medicine” and “supplement”, are everyday usage.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, author or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric result of any kind; evidence strength is expressed qualitatively.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map one-to-one to the “Populations who should avoid CDP-Choline” list inside that ER section (lines 297-303).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER avoid-populations are present, in ER order, with none added or dropped.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements at QRS lines 567-573 inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER rationales are stripped: “the contraindication stated in the European prescribing information”, “in whom any choline load worsens the odour phenotype”, “for whom controlled safety data are absent”, “given reduced clearance of trimethylamine N-oxide”. No dashes carry trailing clauses.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Retained: “(FMO3 deficiency)”, “stage 4 or worse (below 30 mL/min/1.73 m²)”, “(below 50 bpm)”, and the “untreated” qualifier on orthostatic hypotension.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s avoid-populations list uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, correctly: the ER names seven such populations.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map to ER interaction bullets at lines 279-293.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Seven of the ER’s eight interaction bullets are carried; meclofenoxate is correctly excluded because it appears in the Contraindications gate as “Concurrent meclofenoxate”.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven <li> elements at QRS lines 581-590 inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The Caution/Monitor verdicts and every mechanistic sentence are stripped; the em-dash gloss “— dementia medicines that raise acetylcholine levels” is removed from the cholinesterase-inhibitor item.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER example-drug list is preserved: “(Sinemet, Madopar)”, “(donepezil, rivastigmine, galantamine)”, “(oxybutynin, scopolamine, diphenhydramine, benztropine)”, “(alpha-GPC, choline bitartrate, phosphatidylcholine, lecithin)”, “(piracetam, aniracetam, phenylpiracetam)”, “(caffeine, methylphenidate, modafinil)”, and the beta-blocker / calcium channel blocker examples.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets use no ranking notation inside parentheses; all parentheticals are plain comma-separated drug lists.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, correctly: the ER names eight interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol bullets at lines 325, 327 and 335.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, clinical dose regimen and timing are the three executable decisions; the remaining ER bullets are background (half-life, popularising groups, genetics) or downstream of the dose choice.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section carries thirteen bullets, well above three.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content; no placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Memory at 12 weeks and attention at hours-to-28-days come from ER line 382; brain energy reserves at 6 weeks from ER line 197. These are the only three timed readouts in the ER.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered Memory (ER High tier) → Attention and reaction time (ER Low tier) → Brain energy reserves (ER Speculative tier).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, filling all three sets.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans carry ER-derived content; no placeholder text remains.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (lines 197 and 382), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All six ER benefit headings are represented, each in its ER tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at QRS lines 542-557.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier reduces to the ER headings alone; the ER’s “⭕️ Not Central to Health & Longevity” and “⚠️ Conflicted” qualifiers and every Magnitude: figure are stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers carry at least one item, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All six ER risk headings are represented, each in its ER tier.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at QRS lines 602-617.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier reduces to the ER headings alone; “⚠️ Conflicted” markers and all Magnitude: text are stripped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER’s “(slow heart rate)” and “(low blood pressure)” glosses are not carried; no parentheses appear in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER’s High tier carries no risk item (line 221), and risks_high is correctly emptied and set to style="display: none" at QRS line 602.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER Monitoring Protocol & Defining Success biomarker table (lines 412-420).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER rows present in ER order, with targets verbatim: plasma free choline 8–12 µmol/L, homocysteine < 8 µmol/L, TMAO < 5 µmol/L, blood pressure < 120/80 mmHg, resting heart rate 55–70 bpm, ALT 10–26 / 8–22 U/L, and the cognitive battery composite.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 731: baseline and 4-week blood pressure and pulse, cognitive battery at 12 weeks, full fasting panel at 6 to 12 months, matching ER line 410.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the “Qualitative markers worth tracking alongside the laboratory panel” list at ER lines 424-429.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present, verbatim and in ER order.

Issues 18/09/2026 08:39

Pass rate 100.00%. No issues found.

Issues 18/09/2026 08:32

1. 2.7 — Unglossed “parenteral” in Monitoring: marker_5_why (line 693) reads “high-dose parenteral use”; the ER writes “parenteral (injected)” (ER line 249), so the specialist term reaches the sheet without the plain-language equivalent the ER supplies.
2. 2.8 — Time-to-effect subs restate their values: time_2_sub (line 516) restates time_2_value “Hours to 28 days” almost word for word, and time_1_sub (lines 502-503) restates time_1_value “12 weeks”; both consume one-page budget without adding information.

Fixes 18/09/2026 08:32

1. 2.7 — Plain-language wording for parenteral: Changed marker_5_why from “reported with high-dose parenteral use” to “reported with high-dose injected use”, matching the ER’s own gloss “parenteral (injected)”.
2. 2.8 — Time-to-effect subs no longer restate values: Rewrote time_1_sub to “The realistic assessment window; the point at which controlled-trial memory endpoints read out” and time_2_sub to “From a single 28-day controlled trial; the attention signal is unreplicated in adults”, so neither repeats its value cell.